Telix Pharmaceuticals (NASDAQ:TLX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Telix Pharmaceuticals (NASDAQ:TLX) from a sell rating to a hold rating in a report released on Friday morning.

A number of other equities research analysts have also recently issued reports on TLX. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday. Canaccord Genuity Group upgraded shares of Telix Pharmaceuticals to a “strong-buy” rating in a research note on Monday, October 6th. Finally, Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Telix Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Trading Down 0.1%

TLX opened at $7.61 on Friday. The business’s 50-day simple moving average is $8.44 and its 200 day simple moving average is $10.28. Telix Pharmaceuticals has a 52-week low of $7.16 and a 52-week high of $30.36.

Hedge Funds Weigh In On Telix Pharmaceuticals

Large investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in Telix Pharmaceuticals in the 3rd quarter valued at $1,883,000. Pier Capital LLC bought a new stake in shares of Telix Pharmaceuticals in the second quarter valued at about $3,037,000. Portland Investment Counsel Inc. acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,225,000. Lazard Asset Management LLC acquired a new position in shares of Telix Pharmaceuticals in the third quarter valued at about $1,097,000. Finally, Russell Investments Group Ltd. bought a new position in Telix Pharmaceuticals during the second quarter worth about $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.